Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: Lack of significance for microvessel density analysis

Urology

Volumn 51, Issue 1, 1998, Pages 79-85

  Gettman, Matthew T ^a   Bergstralh, Erik J ^a   Blute, Michael ^a   Zincke, Horst ^a   Bostwick, David G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PATHOLOGICAL ANATOMY; PLOIDY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; SCORING SYSTEM; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0031891636     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00464-0     Document Type: Article

References (41)

1. Myers RP, and Fleming TR: Course of localized adenocarcinoma of the prostate treated by radical prostatectomy. Prostate 4: 461-472, 1983.
2. Zeitman AL, Shipley WU, and Willett CG: Residual disease after radical surgery or radiation therapy for prostate cancer. Cancer 71: 959-969, 1993.
3. Blute ML, Nativ O, Zincke H, Farrow GM, Therneau T, and Lieber MM: Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol 142: 1262-1265, 1989.
4. Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt JT, and Zincke H: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical prostatectomy. J Urol 156: 137-143, 1996.
5. Wakui S, Furusato M, Itoh T, Sasaki H, Akiyama A, Kinoshita I, Asano K, Tokuda T, Aizawa S, and Ushigome S: Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol 168: 257-262, 1992.
6. Brawer MK, Bigler SA, and Deering RE: Quantitative morphometric analysis of the microcirculation in prostate carcinoma. J Cell Biochem 16H: 62-64, 1992.
7. Weidner N, Carroll P, Flax J, Blumenfeld W, and Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-407, 1993.
8. Fregene TA, Khanuja PS, Noto AC, Gehani SK, Egmont EM, Luz DA, and Pienta KJ: Tumor-associated angiogenesis in prostate cancer. Anticancer Res 13: 2377-2381, 1993.
9. Bigler SA, Deering RE, and Brawer MK: Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24: 220-226, 1993.
10. Montironi R, Galluzzi CM, Damanati L, Taborro R, Scarpelle M, and Pisani E: Prostatic intra-epithelial neoplasia. Qualitative and quantitative analyses of the blood capillary architecture on thin tissue sections. Pathol Res Pract 189: 542-548, 1993.
11. Brawer MK, Deering RE, Brown M, Preston SD, and Bigler SA: Predictors of pathologic stage in prostatic carcinoma: the role of neovascularity. Cancer 73: 678 -687, 1994.
12. Hall MC, Troncoso P, Pollack A, Zhau HY, Zagars GK, Chung LW, and von Eschenbach AC: Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 44: 869-875, 1994.
13. Vesalainen S, Lipponen P, Talja M, Alhava E, and Syrjanen K: Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma. Anticancer Res 14: 709-714, 1994.
14. Brawer MK, Jonsson E, Gibbons RP, Deering RE, Bigler SA, and Preston SD: Extent of prostate neovascularity predicts progression in patients with pathologic stage C adenocarcinoma treated with radical prostatectomy (abstract). J Urol 151: 289A, 1994.
15. Seigel JA, Yu E, and Brawer MK: Topography of neovascularity in human prostate carcinoma. Cancer 75: 2545-2551, 1995.
16. Andrawis RI, Nashid NS, Lindquist RR, Fitzgerald J, Albertsen PC, Walzak MP, and Kreutzer D: Angiogenesis in prostate cancer and benign prostatic hyperplasia (abstract). J Urol 155: 353A, 1996.
17. Silberman MA, Partin AW, Veltri RW, and Epstein JI: Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 79: 772-779, 1997.
18. Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MA, Fradet Y, et al: Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 48: 47-57, 1996.
19. Brawer MK: Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma. Cancer 78: 345-349, 1996.
20. Vélendzas DG, Wang JP, Droller M, Levine AC, and Kirschenbaum A: Microvessel density in benign prostatic hyperplasia, high grade prostatic intraepithelial neoplasia and prostate cancer (abstract). J Urol 155: 554A, 1996.
21. Salamao DR, Graham SD, and Bostwick DG: Microvascular invasion in prostate cancer correlates with pathologic stage. Arch Pathol Lab Med 119: 1050-1054, 1995.
22. Bahnson RR, Dresner SM, Gooding W, and Becich MJ: Incidence and prognostic significance of lymphatic and vascular invasion in radical prostatectomy specimens. Prostate 15: 149-155, 1989.
23. Weidner N, Semple JP, Welch WR, and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
24. Jaeger TM, Weidner N, Chew K, Moore DH, Kerschmann RL, Waldman FM, and Carroll PR: Tumor angiogenesis correlates with lymph node metastasis in invasive bladder cancer. J Urol 154: 69-71, 1995.
25. Macchiarini P, Fontanni G, Hardin MJ, Squantini F, and Angeletti CA: Relation of neovascularity to metastases of non small cell lung cancer. Lancet 340: 145-146, 1992.
26. Saclarides TJ, Speziale NJ, Drab E, Szeluga DJ, and Rubin DB: Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum 37: 921-927, 1994.
27. MacLennan GT, and Bostwick DG: Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology 46: 27-30, 1995.
28. Gleason DF, and the Veterans Administration Cooperative Urological Research Group: Histologic grading and clin-ical staging of prostatic carcinoma: the prostate, in Tannenbaum M: Urologie Pathology. Philadelphia, Lea and Febiger, 1977, pp 171-187.
29. Kramer SA, Spahr J, Brendler CB, Glenn JF, and Paulson DF: Experience with Gleason's histopathologic grading in prostate cancer. J Urol 124: 223-225, 1980.
30. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine E, Freiha FS, and Stamey TA: Patterns of progression in prostate cancer. Lancet 1: 60-64, 1986.
31. Stamey TA, McNealJE, Freiha FS, and Redwine E: Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 139: 1235-1241, 1988.
32. Winkler HZ, Rainwater LM, Myers RP, Farrow GM, Therneau TM, Zincke H, and Lieber MM: Stage Dl prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. Mayo Clin Proc 63: 103-112, 1988.
33. Lerner SE, Seay TM, Blute ML, Bergstralh EK, Barrett D, and Zincke H: Prostate specific antigen detected prostate cancer (clinical stage TIC): an interim analysis. J Urol 155: 821-826, 1996.
34. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, and Pavone-Macaluso M: The TMN classification of prostate carcinoma. Prostate 4(suppl): 129-138, 1992.
35. Ormanns W, and Schaffer R: An alkaline-phosphate staining method in avidin-biotin immunohistochemistry. Histochemistry 82: 421-424, 1985.
36. Klee GG, Dodge LA, Zincke H, and Oesterling JE: Measurement of serum prostatic specific antigen using Imx prostate specific antigen assay. J Urol 151: 94-98, 1994.
37. McNeal JE: Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol 23: 258-266 1992.
38. Epstein JI, Carmichael M, Partin A, and Walsh PC: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinoma of the prostate with 5 years of follow-up. J Urol 149: 1478-1481, 1993.
39. Epstein JI, Walsh PC, Carmichael M, and Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage Tic) prostate cancer. JAMA 271: 368-374, 1994.
40. Craft PS, and Harris AL: Clinical prognostic significance of tumour angiogenesis. Ann Oncol 5: 305-311, 1994.
41. Horak ER, Leek R, Klenk N, Le Jeune S, Smith N, Greenall M, Stephaniewska K, and Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120-1124, 1992.